Changes in skeletal muscle loss between cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer

Changes in skeletal muscle loss between cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer - Changes in skeletal muscle loss between cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027812

Enrollment

100

Registered

2017-06-20

Start date

2017-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with pathologically proven Non-small cell lung cancer stage4

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically confirmed NSCLC stage4 according to UICC TNM stage classification, the administration of first-line chemotherapy, and a clear before and after CT image (coverage of L2 and L3 vertebral body).

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Muscle mass was measured with a single cross-sectional area of the muscle at the third lumber vertebra (L3MA). To estimate skeletal muscle changes during chemotherapy, we set the following L3 muscle index (L3SMI) ratio: post L3SMI / pre L3SMI.	—

Countries

Japan

Contacts

Public ContactKazutaka Kakinuma

Internal Medicine Division of Respiratory Medicine

k2kakinuma@marianna-u.ac.jp044-977-8111

Outcome results